Amgen Inc. (AMGN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Amgen Inc. stock price, AMGN
Amgen Inc. stock chart:
Amgen Inc. close price: 165.74
Stock price forecast:
DOWN TO -5.04%
Total forecasts: 89
Reached: 31 (34.83%)
Total Win: 75.18 (49.69%)
Showing 1-10 of 510 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Amgen Inc. latest news:
Wall St. flat as banks, Amgen weigh; Adobe rallies
NEW YORK (Reuters) - U.S. stocks dipped on Friday as bank shares fell alongside Treasury yields while Adobe helped buoy the S&P tech sector and the Nasdaq Composite.
Wall Street little changed as healthcare stocks weigh
(Reuters) - U.S. stocks were little changed on Friday as a slide in Amgen dragged down the healthcare sector, offsetting gains in technology shares.
Data on heart benefits of Amgen drug is key to unlocking sales
March 13 (Reuters) - Data that should help unlock the sales
potential of a potent new cholesterol medicine will be unveiled
at the American College of Cardiology meeting this week as the
future of the only rival drug rests with the courts in an
ongoing patent dispute.
Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug
Advaxis Inc. shares surged 10.6% in pre-market trade Monday after the company said the Food and Drug Administration would allow its ADXS-NEO, a cancer immunotherapy drug partnership with Amgen , to proceed to clinical trials. ADXS-NEO's approach targets neoantigens, which are seen as a promising avenue of cancer drug development, and the drug is only the second of this type with an Investigational New Drug application accepted by the FDA, according to a company spokesperson. Advaxis said it plans to start a phase 1 trial for the drug in multiple tumor types later this year. Amgen shares slumped 0.2% in pre-market trade Monday. Shares of Advaxis have risen 3.5% over the last three months, and shares of Amgen have surged 24.2% over the last three months, compared with a 7.7% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
George Soros picks up Goldman Sachs, dumps Nvidia
George Soros's hedge fund Soros Fund Management made a lot of changes to his portfolio in the fourth quarter, dumping positions in many companies and initiating positions in Goldman Sachs Group Inc. and Pandora Media Inc. . Soros decreased positions in Abbott Labs , Amazon.com Inc. , eBay Inc. , Netflix Inc. , and VMware Inc. . Soros also dumped positions in Activision Blizzard Inc. , Amgen Inc. , Barrick Gold Corp. , Coca-Cola Co. and Nvidia Corp. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now
A federal appeals court temporarily stopped another judge's decision that would have forced Regeneron and Sanofi (SNY) to stop selling cholesterol drug Praluent. The Tuesday decision, though expected, "means that Praluent will not come off the market by Feb. 21," and could even stay on the market through the rest of the year, said Evercore ISI analyst Mark Schoenebaum. The previous judge's decision in favor of Amgen Inc. (AMGN) was a for Amgen (AMGN), and sent its shares up on Jan. 7, the day the decision...
BRIEF-Amgen CEO expects to see U.S. tax reform
* Amgen CEO says international expansion important element
of long-term growth
Amgen fourth quarter profit tops Street view, but 2017 outlook light
(Reuters) - Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates.
U.S. Judge Blocks Sanofi and Regeneron From Selling Cholesterol Drug
A federal judge on Thursday blocked Sanofi SA and Regeneron Pharmaceuticals Inc from selling their cholesterol drug Praluent, a victory for Amgen Inc, which had accused them of infringing its patents.
Amgen shares soar as judge blocks sales of Regeneron drug
Shares of Regeneron Pharmaceuticals Inc. were halted in the extended session Thursday while shares of Amgen Inc. rallied after a federal judge said Regenron had to pull its competing cholestrol drug off the market as a penalty in a patent lawsuit. Regeneron shares were halted at $376.61, down 1.1% after hours, while shares of Amgen jumped 4.6% to $160. On Thursday, a federal judge blocked sales of Regeneron's cholesterol treatment Praluent, stating that "irreparable harm" had been done to Amgen's Repatha. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amicus Therapeutics, Inc.FOLD
Amkor Technology, Inc.AMKR
Amphastar Pharmaceuticals, Inc.AMPH
Amtech Systems, Inc.ASYS
AmTrust Financial Services, Inc.AFSI+26.7%
Anacor Pharmaceuticals, Inc.ANAC